# Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

> **NCT07492160** · PHASE2 · RECRUITING · sponsor: **Maimonides Medical Center** · enrollment: 348 (estimated)

## Conditions studied

- Pregnancy
- Abortion

## Interventions

- **DRUG:** Cabergoline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07492160
- **Lead sponsor:** Maimonides Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2028-02
- **Final completion:** 2028-04
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492160, "Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07492160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*